Press Releases

Atomwise Inc. today announced a multi-year agreement with Eli Lilly and Company to apply Atomwise’s patented artificial intelligence (AI) technology in support of Lilly’s preclinical drug discovery efforts. The companies will collaborate on up to ten drug targets selected by Lilly, with the goal of accelerating the time it takes to identify and develop potential […]

Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development   GENEVA, Switzerland and SAN FRANCISCO, USA (April 16, 2019) – Atomwise, Inc., a biotech company using artificial intelligence (AI) for drug discovery, and the Drugs for Neglected […]

A half dozen University of Connecticut (UConn) researchers are now working to identify potential new drugs to treat a wide range of diseases and conditions through a unique partnership that offers access to cutting-edge artificial intelligence (AI) technology and screening compounds at no cost. The researchers have been using Atomwise’s AI-powered in silico screening technology […]

Charles River reaffirms commitment to the future of drug discovery by advancing the Company’s integrated, innovative early-stage platform WILMINGTON, Mass., and SAN FRANCISCO, Calif., January 11, 2019 – Charles River Laboratories International, Inc. (NYSE: CRL) and Atomwise, Inc. today announced the formation of a strategic alliance that offers clients access to Atomwise’s artificial intelligence (AI)-powered, […]

Charles River’s clients gain access to Atomwise’s Artificial Intelligence (AI) technology to improve novelty, quality and efficiency of preclinical drug discovery. SAN FRANCISCO, January 11, 2019 – Atomwise, Inc. today announced a strategic alliance with Charles River Laboratories International, Inc., which will offer biotech and pharmaceutical companies an end-to-end drug discovery solution that unites AI […]

Atomwise Inc., a leader in Artificial Intelligence (AI) for drug discovery and design, has entered into an evaluation agreement with Pfizer Inc. (NYSE: PFE). Pfizer will evaluate Atomwise’s platform to identify potential drug candidates for up to three target proteins selected by Pfizer. In the agreement, Pfizer will pay a technology access fee and additional […]